Interview with Brigitte Widemann, MD about Koselugo (selumetinib) the First FDA Approved Drug for NF

In this interview, NF1 patient Aidan Fraser discusses the development of the MEK-inhibitor drug Koselugo (selumetinib) with his doctor, Brigitte Widemann, MD, who was the principal investigator of the selumetinib clinical trial at the National Institutes of Health. Aidan lives with NF1 and was on the selumetinib clinical trial for many years. In this interview, Aidan and Brigitte are speaking to each other from their respective homes, as an in-person interview was cancelled due to the COVID-19 social distancing guidelines. Learn more about the history of the first FDA-approved drug for NF at: ctf.org/progress Click the CC button to enable Closed Captioning. What is the Children's Tumor Foundation? Children’s Tumor Foundation (CTF) began as the first grassroots organization solely dedicated to finding treatments for NF. Today, CTF is a highly recognized global nonprofit foundation, the leading force in the fight to end NF, and a model for other innovative research endeavors. Visit our website at https://www.ctf.org/ Donate today at https://www.ctf.org/ways-to-give/ Follow us on our social media platforms: Facebook -   / childrenstumor   Instagram -   / childrenstumor   Twitter -   / childrenstumor   LinkedIn -   / children's-tumor-foundation   #endnf #nf1 #nf2 #nf2swn #swn #childrenstumor #neurofibromatosis #schwannomatosis #nervetumor #tumor